Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
Dolores Isla,Carme Sarries,Rafael Rosell,Guillermo Alonso,Manuel Domine,Miquel Taron,Guillermo Lopez-Vivanco,Carlos Camps,M. Botia,L. Nuñez,Maria Sanchez-Ronco,Jose Javier Sanchez,Marta López-Brea,Isidoro Barneto,A. Paredes,B. Medina,Angel Artal,Pilar Lianes +17 more
Reads0
Chats0
TLDR
ERCC1 SNP assessment could be an important component of tailored chemotherapy trials and patients homozygous for the ERCC1 118 C allele demonstrated a significantly better survival.About:
This article is published in Annals of Oncology.The article was published on 2004-08-01 and is currently open access. It has received 287 citations till now. The article focuses on the topics: ERCC1 & Docetaxel.read more
Citations
More filters
Journal ArticleDOI
Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer
TL;DR: No reproducible significant associations between genotype and outcome or toxicity were found for any of the genes analyzed in this large study of a well-defined patient population within one specific clinical trial, highlighting the need for validation of putative genetic markers in large, well- defined clinical sample sets.
Journal ArticleDOI
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
Carmelo Tibaldi,Elisa Giovannetti,Enrico Vasile,Valentina Mey,A.C. Laan,S. Nannizzi,R. Di Marsico,Andrea Antonuzzo,Cinzia Orlandini,S. Ricciardi,M. Del Tacca,G.J. Peters,Alfredo Falcone,Romano Danesi +13 more
TL;DR: The role of CDA Lys27Lys polymorphism is suggested as a possible predictive marker of activity, toxicity, TTP, and OS in advanced NSCLC patients treated with cisplatin and gemcitabine.
Journal ArticleDOI
Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy
Pascal Sève,Sylvie Isaac,Olivier Tredan,Pierre-Jean Souquet,Yves Pacheco,Maurice Pérol,Laurence Lafanechère,Aurélie Penet,Eva-Laure Peiller,Charles Dumontet +9 more
TL;DR: It is suggested that a high level of expression of class III β-tubulin in tumor cells is associated with resistance to vinorelbine and a poor prognosis in patients with NSCLC receiving vinORElbine-based chemotherapy.
Journal ArticleDOI
ATP-binding cassette (ABC) transporters in normal and pathological lung
Margaretha van der Deen,Elisabeth G.E. de Vries,Wim Timens,Rik J. Scheper,Hetty Timmer-Bosscha,Dirkje S. Postma +5 more
TL;DR: This review aims to give new insights in the possible functions of ABC molecules in the lung in view of their expression in different cell types, and the role in protection against noxious compounds, e.g. air pollutants and cigarette smoke components, is discussed.
Journal ArticleDOI
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea.
TL;DR: For moderately to highly emetogenic chemotherapy, standard prophylactic treatment is an antagonist for 5-hydroxytryptamine 3 receptors (5-HT3R) combined with dexamethasone for the acute phase, and dexamide with another agent for prevention of the delayed phase as discussed by the authors.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
Frank V. Fossella,José Rodrigues Pereira,Joachim von Pawel,Anna Pluzanska,Vera Gorbounova,E. Kaukel,K. Mattson,Rodryg Ramlau,Aleksandra Szczesna,Panagiotis Fidias,Michael Millward,Chandra P. Belani +11 more
TL;DR: DC resulted in a more favorable overall response and survival rate than VC, demonstrating that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
Journal Article
Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans.
Shen Mr,Jones Im,Mohrenweiser H +2 more
TL;DR: Estimation of the extent of DNA sequence variation among individuals in genes encoding proteins of the DNA repair pathways finds nine different amino acid substitution variants have been identified in resequencing of the exons of three nucleotide excision repair genes, a gene involved in double-strand break repair/recombination genes, and a gene functioning in base excision Repair and the repair of radiation-induced damage.
Journal Article
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Reginald V. Lord,Jan Brabender,David R. Gandara,Vicente Alberola,Carlos Camps,Manuel Domine,Felip Cardenal,Jose Miguel Sanchez,Paul H. Gumerlock,Miquel Taron,Jose Javier Sanchez,K. D. Danenberg,Peter V. Danenberg,Rafael Rosell +13 more
TL;DR: Everexpression of the excision repair cross-complementing 1 (ERCC1) gene is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC and the presence of weight loss were significant prognostic factors for survival in a Cox proportional hazards multivariable analysis.
Journal ArticleDOI
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.
Asra Siddiqui,Reinhold Kerb,Michael E. Weale,Ulrich Brinkmann,Alice Smith,David Goldstein,Nicholas W. Wood,Sanjay M. Sisodiya +7 more
TL;DR: Patients with drug-resistant epilepsy were more likely to have the CC genotype at ABCB1 3435 than the TT genotype, implying that the polymorphism may not itself be causal but rather may be linked with the causal variant.
Related Papers (5)
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
M. Cobo,Dolores Isla,Bartomeu Massuti,Ana Montes,Jose Miguel Sanchez,Mariano Provencio,Nuria Viñolas,Luis Paz-Ares,Guillermo Lopez-Vivanco,Miguel Angel Muñoz,Enriqueta Felip,Vicente Alberola,Carlos Camps,Manuel Domine,Jose Javier Sanchez,Maria Sanchez-Ronco,K. D. Danenberg,Miquel Taron,David R. Gandara,Rafael Rosell +19 more